IMP4927
Phase 3Small molecule
IMP4927 is one of 50 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
232 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Hycamtin
MMeitheal
Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Femara
NovartisPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rubraca
Bristol-Myers SquibbPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Neulasta
AmgenPhase 3
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMP4927. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IImpact Therapeutics, Inc.